582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

• Kevin Kelly,
• Matt Coffey,
• Tomás Pascual,
• Aleix Prat,
• Luis Manso,
• Thomas Heineman,
• Fernando Salvador,
• Joaquín Gavilá,
• Houra Loghmani,
• Richard Trauger,
• Akil Merchant,
• Julian Olea,
• Homa Dadrastoussi,
• Eduardo Fernandez Hernandez,
• Hugo Lara Martinez,
• Kaijin Wu

Affiliations

Kevin Kelly

2Healthier Workforce Center of the Midwest, Iowa City, USA

Matt Coffey

Oncolytics Biotech Inc, Calgary, Alberta, Canada

Tomás Pascual

Aff1 grid.10403.36Translational Genomics and Targeted Therapeutics in Solid TumorsIDIBAPS Barcelona Spain

Aleix Prat

Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

Luis Manso

7Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain

Thomas Heineman

16Oncolytics Biotech Inc., San Diego, CA, USA

Fernando Salvador

1 Departament of Biochemistry, Universidad Autónoma de Madrid (UAM), Departament of Cancer Biology, Instituto de Investigaciones Biomédicas Alberto Sols CSIC-UAM, Madrid, Spain

Joaquín Gavilá

7Instituto Valenciano de Oncología (IVO), Valencia, Spain

Houra Loghmani

1Oncolytics Biotech Inc., San Diego, United States

Richard Trauger

1Oncolytics Biotech Inc., San Diego, United States

Akil Merchant

3Cedars-Sinai Medical Center, Los Angeles, CA, USA

Julian Olea

1University of Southern California, Los Angeles, CA, USA

Homa Dadrastoussi

1University of Southern California, Los Angeles, CA, USA

Eduardo Fernandez Hernandez

1University of Southern California, Los Angeles, CA, USA

Hugo Lara Martinez

1University of Southern California, Los Angeles, CA, USA

Kaijin Wu

1University of Southern California, Los Angeles, CA, USA